BALCAO · WHOLESALE-DRUGS, PROPRIETARIES & DRUGGISTS' SUNDRIES · SMALL CAP
Stemtech Corp. STEK
16 fiscal years on record · USD · FY2025 reported · SEC filings only
Growth
USD 2.9M
Revenue, FY2025 · full 16-year series below
Revenue $M
Net income $M
FY2025 · Revenue 2.9 · Net income -4.0
Compound annual growth
Revenue compounded at −8.1% a year over five years.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
−141 cents
lost on every revenue dollar
Operating margin
Net margin
FY2025 · Operating -94.2% · Net -140.8%
ROE
No chart to show — the reason differs by year; see each year in the table below.
The 16-year record
16 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · | · | · | · | · | · | · | · | · | · |
| Operating income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | · | · |
| EBITDA $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | · | · | · | · | · | · | · | · | · | · |
| Income tax $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | −0.0 | · | · | · | · | · | 0.0 | 0.0 | · | · | · |
| Net income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| Free cash flow $B | −0.0 | −0.0 | −0.0 | · | · | −0.0 | · | · | · | · | · | · | · | · | · | · |
| EPS, diluted $ | −0.02 | −0.03 | −0.07 | −0.19 | −0.20 | −0.10 | −0.00 | −0.00 | −0.00 | −0.00 | −0.00 | −0.00 | −0.00 | −0.00 | · | · |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| ROE % | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| Shares out B | 0.43 | 0.14 | 0.10 | 0.05 | 0.04 | 0.03 | · | · | · | · | · | · | · | · | · | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Compare
This company against its peers
Stemtech Corp.vsMckesson Corp.Same industry: Wholesale-Drugs, Proprietaries & Druggists' SundriesStemtech Corp.vsCencora, Inc.Same industry: Wholesale-Drugs, Proprietaries & Druggists' SundriesStemtech Corp.vsCardinal Health Inc.Same industry: Wholesale-Drugs, Proprietaries & Druggists' SundriesStemtech Corp.vsHerbalife Ltd.Same industry: Wholesale-Drugs, Proprietaries & Druggists' SundriesStemtech Corp.vsNU Skin Enterprises, Inc.Same industry: Wholesale-Drugs, Proprietaries & Druggists' SundriesStemtech Corp.vsCosmos Health Inc.Same industry: Wholesale-Drugs, Proprietaries & Druggists' SundriesStemtech Corp.vsCellyan Biotechnology Co. Ltd.Same industry: Wholesale-Drugs, Proprietaries & Druggists' Sundries
Provenance
Company facts, as filed
How we verify · 0 failures in 64 reconciliationsAUDITED
Reconciled in 16 of 19 fiscal years. 31 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityWholesale-Drugs, Proprietaries & Druggists' Sundries
Listed onOTC market
Incorporated innot stated in the filings
Fiscal year endsDecember 31
SEC categoryemerging growth company, smaller reporting company
Data on record since2010